129 related articles for article (PubMed ID: 9885304)
21. Use of in vitro release tests for the prediction of the in vivo behavior and the development of flucytosine controlled-release capsules.
Bonny JD; Kyowa M
J Pharm Sci; 1995 May; 84(5):619-23. PubMed ID: 7658354
[TBL] [Abstract][Full Text] [Related]
22. Lack of effect of multiple dose sucralfate on the pharmacokinetics of of roxatidine acetate.
Seibert-Grafe M; Pidgen A
Eur J Clin Pharmacol; 1991; 40(6):637-8. PubMed ID: 1679394
[No Abstract] [Full Text] [Related]
23. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
Murdoch D; McTavish D
Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
[TBL] [Abstract][Full Text] [Related]
24. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
Hemery P; Congard P; Galmiche JP; Bonfils S
Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
[TBL] [Abstract][Full Text] [Related]
25. Twenty-four-hour intragastric acidity following early evening or bedtime administration of roxatidine in duodenal ulcer patients.
Lazzaroni M; Sangaletti O; Bargiggia S; Bensi G; Canali A; Bianchi Porro G
Aliment Pharmacol Ther; 1996 Apr; 10(2):187-91. PubMed ID: 8730248
[TBL] [Abstract][Full Text] [Related]
26. In vitro-in vivo correlation of a modified-release oral form of ketotifen: in vitro dissolution rate specification.
Humbert H; Cabiac MD; Bosshardt H
J Pharm Sci; 1994 Feb; 83(2):131-6. PubMed ID: 8169778
[TBL] [Abstract][Full Text] [Related]
27. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
28. Biopharmaceutical characterization of sustained release matrix tablets based on novel carbomer polymers: formulation and in vivo investigation.
Jelena P; Djurić Z; Jovanović M; Ibrić S; Kilibarda V; Jovanović D; Evic IK
Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):99-104. PubMed ID: 16010868
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic characteristics of roxatidine.
Bender W; Brockmeier D
J Clin Gastroenterol; 1989; 11 Suppl 1():S6-19. PubMed ID: 2572622
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo evaluation of single-unit commercial immediate-and sustained-release capsules compared with multiple-unit polystyrene microparticles dosage forms of indomethacin.
Tamilvanan S; Sa B
PDA J Pharm Sci Technol; 2008; 62(3):177-90. PubMed ID: 18661867
[TBL] [Abstract][Full Text] [Related]
31. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa F; Klein S
J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
[TBL] [Abstract][Full Text] [Related]
32. Preparation and in vitro/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets.
Liu Y; Sun Y; Sun J; Zhao N; Sun M; He Z
Int J Pharm; 2012 Apr; 426(1-2):21-28. PubMed ID: 22266529
[TBL] [Abstract][Full Text] [Related]
33. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules.
Kortejärvi H; Mikkola J; Bäckman M; Antila S; Marvola M
Int J Pharm; 2002 Jul; 241(1):87-95. PubMed ID: 12086724
[TBL] [Abstract][Full Text] [Related]
34. Biopharmaceutical characterization of carbamazepine immediate release tablets. In vitro-in vivo comparison.
Homsek I; Parojcic J; Cvetkovic N; Popadic D; Djuric Z
Arzneimittelforschung; 2007; 57(8):511-6. PubMed ID: 17915636
[TBL] [Abstract][Full Text] [Related]
35. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
Möller H; Wirbitzki E
Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
[TBL] [Abstract][Full Text] [Related]
36. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC).
Hayes S; Dunne A; Smart T; Davis J
J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896
[TBL] [Abstract][Full Text] [Related]
37. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
[TBL] [Abstract][Full Text] [Related]
38. Floating drug delivery of a locally acting H2-antagonist: an approach using an in situ gelling liquid formulation.
Rohith G; Sridhar BK; Srinatha A
Acta Pharm; 2009 Sep; 59(3):345-54. PubMed ID: 19819830
[TBL] [Abstract][Full Text] [Related]
39. [Circadian aspects of diclofenac gastroduodenopathy and the protective effect of roxatidine].
Müller P; Jackisch P; Simon B
Z Rheumatol; 1993; 52(5):297-300. PubMed ID: 7903132
[TBL] [Abstract][Full Text] [Related]
40. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
